Genomelink vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
Genomelink logo

Genomelink

EmergingHealthcare

General

DNA app store enabling users to upload Ancestry/23andMe raw data for additional trait and health insights; $3.3M revenue positioned to capture 23andMe users after its 2024 bankruptcy filing.

AI VisibilityBeta
Overall Score
C40
Category Rank
#390 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
35
Gemini
41

About

Genomelink is a San Francisco-based DNA app store and personalized genomics platform that allows users to upload raw DNA data from Ancestry, 23andMe, or other consumer DNA tests and access a marketplace of analysis apps covering ancestry, traits, health predispositions, and wellness insights. Founded in 2017 and backed by $4.5-9 million from 500 Global, Asymmetry Ventures, and 27 total investors, Genomelink generated $3.3 million in revenue in 2024 with a 22-person team, serving consumers who want more from their raw genetic data than the original testing company provides.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#390
Category Rank
#2
73
AI Consensus
83
stable
Trend
stable
34
ChatGPT
92
35
Perplexity
93
41
Gemini
89
42
Claude
96
44
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.